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Abstract 
 
Objective: Resource allocation informed by cost-utility analysis requires that the benefits are 
comparable across patient groups and interventions. One option is to recommend the use of 
one generic utility measure, but this raises the issue of comparability when the preferred 
measure is inappropriate or unavailable. Many cancer trials do not include generic measures 
such as EQ-5D and instead include condition-specific measures and use these to generate 
utility estimates. We analyse the comparability of generic, condition-specific and mapped 
utility values for a Multiple Myeloma cancer patient dataset. 
 
Methods: Generic EQ-5D, condition-specific EORTC-8D and mapped EQ-5D utility values 
are compared using psychometric and statistical analysis to determine discrimination across 
severity groups, responsiveness and agreement. 
 
Results: Generic, condition-specific and mapped utility estimates were responsive and show 
discriminative validity. EQ-5D had higher responsiveness and detected a greater change 
across severity groups and treatment periods than EORTC-8D, but has a higher proportion of 
responses at full health (12.2%). Differences in EQ-5D and EORTC-8D were due to both 
differences in classification system and preference weights. 
 
Conclusion: Our findings suggest that condition-specific EORTC-8D or mapped EQ-5D utility 
estimates are comparable to directly obtained EQ-5D utilities. EORTC-8D estimates captured 
problems in quality of life at the upper end of the utility scale that were not captured by EQ-
5D, but estimated lower utility gains than the use of EQ-5D directly. 
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Introduction 
Resource allocation informed by economic evaluation using cost-utility analysis has become 
increasingly popular in recent years. This analysis requires that the measures of benefit and 
cost for each evaluation are comparable both across different patient groups and different 
interventions. Benefit is measured using quality-adjusted life years (QALYs) which are a 
measure of both quantity and quality of life. Often generic preference-based measures such 
as the EQ-5D (1), HUI3 (2) or SF-6D (3;4) are used to calculate the ‘Q’ component of the 
QALY. However it is well documented that different generic measures produce different 
results when applied to the same patient group at the same point in time (5). This raises 
issues for comparability, and one solution is to recommend the use of a single measure for all 
evaluations. This is the approach taken by the National Institute of Health and Clinical 
Excellence (NICE) (6) where the most commonly used generic measure, EQ-5D, is 
recommended for use in all technology appraisals. This raises the question of how utility 
values should be generated if EQ-5D is either unavailable or inappropriate, and the 
comparability of evaluations undertaken in these circumstances. 
 
Cancer is one condition where it remains unclear whether the generic EQ-5D is appropriate, 
but is further complicated by the fact that EQ-5D is often unavailable as many cancer trials do 
not include it. NICE state that if a measure is thought inappropriate empirical evidence should 
be provided demonstrating why it is inappropriate, covering properties such as content 
validity, construct validity, responsiveness and reliability. A recent report argues that the EQ-
5D may not be sufficiently sensitive to capture changes in health status of cancer patients, as, 
for example, there is no EQ-5D dimension to specifically capture changes in vitality or energy 
(7). However there is little guidance provided by NICE or similar agencies of when a measure 
can be deemed inappropriate for a patient group or intervention, and this is an area requiring 
further research and guidance. If EQ-5D is inappropriate, NICE state that other measures can 
be used (6). 
 
Clinicians and researchers often choose to include condition-specific profile measures in trials 
rather than generic preference-based measures such as EQ-5D. Condition-specific profile 
measures, such as EORTC QLQ-C30 are often included as these capture the effects of 
interventions across a wide range of relevant symptoms, side effects and aspects of 
functioning and quality of life and their validity is well established. These profile measures 
have great clinical utility and are recommended by the US FDA (8), whereas the EQ-5D is 
recommended only for economic evaluation and can be viewed as being an additional burden 
for completion for patients who are very unwell. However these condition-specific profile 
measures typically provide a description rather than a valuation of health and cannot be used 
to populate cost-effectiveness models. In recent years there has been a growth in preference-
based measures derived from existing condition-specific measures that enable these 
measures to be used directly to generate utilities. The EORTC-8D is a recently developed 
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condition-specific preference-based measure derived from EORTC QLQ-C30 for use in 
cancer patients (9). This measure allows a utility estimate to be generated for every individual 
each time the EORTC QLQ-C30 is used and enables the direct estimation of utility without 
placing any burden on patients to complete an extra measure or additional questions. 
Mapping is an alternative method that can be used to obtain utility values when only a 
condition-specific non-preference-based measure was included in the trial. Mapping applies 
the statistical relationship between, for example, QLQ-C30 and EQ-5D to obtain predicted 
EQ-5D values from QLQ-C30 data. This relationship is typically obtained by estimating 
regressions on a separate dataset which has similar patient characteristics to the trial. 
Published mapping algorithms are available that map the condition-specific QLQ-C30 onto 
EQ-5D, and these algorithms can be applied to the trial dataset to produce EQ-5D estimates.  
If EQ-5D is unavailable in a trial, NICE (6) recommend that either mapping or other validated 
measures are used to produce utility values. NICE stipulate that the mapping must be based 
on empirical data and the other measures should have valuation methods that are 
comparable to those used for EQ-5D (MVH tariff) (10). 
 
A small number of studies have examined the impact of using mapped EQ-5D estimates 
rather than directly generated EQ-5D utilities, finding different results across studies (11-13). 
A large number of studies compare the performance of EQ-5D to the other main generic 
preference-based measures such as SF-6D and HUI2 (see (5) for an overview) but there are 
few comparisons of condition-specific and generic preference-based measures (see (14)). 
Furthermore as far as the authors are aware no study has examined the comparability of all 
preferred options for use in technology appraisals to agencies such as NICE; as although EQ-
5D is the preferred option, under certain circumstances other generic, condition-specific or 
mapped EQ-5D utility estimates can be used. 
 
This paper compares utility values generated using the EQ-5D to utilities generated using a 
condition-specific preference-based measure and mapping for a cancer patient dataset. We 
compare utility values obtained using: generic preference-based EQ-5D; condition-specific 
preference-based EORTC-8D derived from EORTC QLQ-C30; and two published algorithms 
mapping QLQ-C30 onto EQ-5D. We further compare the performance of EORTC-8D and 
EORTC QLQ-C30 summary scores to determine whether the EORTC-8D maintains the 
desirable properties of the original measure. This paper seeks to inform researchers and 
policy makers in their choice of source of utility values and interpretation of these values 
regarding discrimination across severity groups, responsiveness and agreement. 
 
Summary of measures 
EQ-5D 
EQ-5D has 5 dimensions (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) each with 3 levels of severity from no problems to severe problems (1). 
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The health state classification system describes 243 unique health states and utility values 
range from 1 to -0.594 for the UK value set collected in the Measuring and Valuing Health 
(MVH) study (10). 
 
EORTC QLQ-C30 and EORTC-8D 
The QLQ-C30 is widely used in cancer clinical trials in Europe and Canada (15) and has been 
found valid for many cancer conditions. The QLQ-C30 has 30 questions that cover functioning 
(physical, role, social, emotional and cognitive functioning) and common cancer symptoms 
(pain, fatigue, nausea, vomiting, dyspnea, appetite loss, sleep disturbance, constipation and 
diarrhea) plus financial impact of the disease and treatment (excluded from analyses here as 
this is inappropriate for inclusion in health-related quality of life measurement to generate 
QALYs). The QLQ-C30 has fourteen summary scales ranging from 0 to 100, each 
representing an aspect of functioning (5 summary scales, higher scores represent higher 
functioning) or a particular symptom (9 summary scales, higher scores represent greater 
symptoms), with one additional global quality of life scale. 
 
The EORTC-8D has 8 dimensions (physical functioning, role functioning, pain, emotional 
functioning, social functioning, fatigue and sleep disturbance, nausea, constipation/diarrhoea) 
each with 4 or 5 levels of severity. The health state classification system was derived from 10 
QLQ-C30 items and describes 81,920 unique health states with a range of utility values from 
1 to 0.291 (9).  
 
Methods 
Utility values were generated using the available preference weights for EQ-5D and EORTC-
8D for each patient at each time point in the dataset. Mapped utility values were also 
estimated for each patient at each time point using published algorithms described below. 
 
Estimating EQ-5D utilities by mapping QLQ-C30 onto EQ-5D 
The easiest way to produce mapped estimates is to use published algorithms. Six published 
algorithms use mapping to produce utilities using EORTC QLQ-C30 data, two of which were 
used here (11;16). The other four algorithms are not used here as one paper requires FACT 
data not available in our dataset (17), one paper maps to patient TTO values rather than EQ-
5D (18), one paper uses only females as their patient group (19), and one paper does not 
publish the mapping function (20). Patient valuations of own health using preference 
elicitation techniques such as time trade-off or visual analogue scales are not preferred by 
agencies such as NICE or Washington Panel of Cost Effectiveness (21) as public preferences 
are preferred given that  public funding is often used to provide healthcare. Patient values can 
also be affected by vested interests and can be difficult to obtain on patients who are very 
unwell as to generate QALYs the utility values must be anchored against death on a full 
health-death 1-0 scale. For mapping to provide accurate and appropriate estimates the 
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patient group used to estimate the mapping algorithm should be representative of the patient 
group it is applied to. Although there is no evidence stating that sex affects the accuracy of 
mapped estimates, given that mapping algorithms estimated using datasets containing both 
sexes are available, these were chosen here in preference. 
 
The first algorithm used here is an algorithm by McKenzie and van der Pol (11), who 
estimated OLS regressions on 877 patients with esophageal cancer. The regression 
equations used here include all 15 functioning scales and symptom scales from the QLQ-C30 
to map onto EQ-5D. McKenzie and van der Pol also report regressions that predict EQ-5D 
responses to each dimension rather than to a utility score, yet found that these performed 
worse and so they are not used here. 
 
The second algorithm by Kontodimopoulos et al. (16) estimated OLS regressions on 48 
patients with gastric cancer. Explanatory variables included in the model were selected using 
a stepwise inclusion procedure and the remaining variables were the physical functioning, 
emotional functioning and global health status scales. 
 
Cancer patient dataset 
The analysis was undertaken for a sample of patients newly diagnosed with multiple myeloma 
cancer.  The data was collected in VISTA, a phase III randomized open-label trial 
(ClinicalTrials.gov number, NCT00111319) completed in June 2007. Patients were requested 
to complete both the EQ-5D and EORTC QLQ-C30 at their screening visit, day 1 of each of 
the 9 cycles of treatment, end of treatment visit and during the post treatment phase (every 6 
or 8 weeks) until disease progression. To remove any differences in analyses due to missing 
values, observations are included in the analysis only where both EQ-5D, EORTC-8D and 
QLQ-C30 items used in each of the mapping algorithms are available.The dataset used here 
contains 5650 observations in total across 674 individuals and 16 time periods (all periods in 
the trial where n>70). Mean age of the sample is 71.58 (standard deviation of 5.25) and 
50.8% of the sample is female. 
 
Analysis 
Psychometric and statistical analyses were used to compare the utility estimates produced 
using different methods and EORTC QLQ-C30 summary scores.  
 
Validity: Discrimination across different severity groups 
Construct validity is examined by assessing ability to discriminate between patients with 
different levels of severity. It is important that a utility measure or method of producing utilities 
can discriminate correctly amongst groups of different severity as this determines whether the 
utility values measure an improvement in quality of life due to a health improvement in the 
condition of interest. The Karnofsky Performance Scale is reported by the doctor and 
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classifies patients according to functional impairment typically using 10 point markers, where 
a score of 100 indicates that the patient is normal with no signs of disease and a score of 0 is 
equivalent to death (22).  As clinical severity is conceptually different to quality of life 
discrimination was also captured across different groups according to self-reported quality of 
life using item 30 from the EORTC QLQ-C30 (‘How would you rate your overall quality of life 
during the past week? Please circle the number between 1 and 7 that best applies to you, 
1=very poor and 7=excellent’). Discrimination was examined using the statistical significance 
of differences using an overall F-test from an ANOVA and the sensitivity of differences using 
standardised effect size (ES). ES is estimated using the difference in mean scores between 
two adjacent sub-groups of study participants with different levels of severity divided by the 
standard deviation of scores for the mildest of the two sub-groups. Utilities were also plotted 
for severity groups categorised according to the Karnofsky Performance Scale and self-
reported quality of life. 
 
Responsiveness to change over time 
Responsiveness is the sensitivity of a measure to known changes in health over time. Here 
this is examined in terms of sensitivity to change in trial data before and after treatment 
across all study arms. Responsiveness was examined using floor and ceiling effects, 
standardised response mean (SRM), ES and t tests. Floor and ceiling effects report the 
percentage of patients in either full health or the most severe health state ‘PITS’, where a high 
percentage indicates that the measure is unable to capture either an improvement or 
deterioration in health respectively. Relative floor and ceiling effects are important as they 
indicate that one measure cannot distinguish whereas another can. SRM is the mean change 
score of a measure between two different time points divided by the standard deviation of the 
change score (23). ES in this case is the mean change score of a measure between two 
different time points divided by the standard deviation of the score at baseline. Standardised 
response mean and effect size are generated to assess the responsiveness of the different 
methods between screening and cycle 9 of the trial and between screening and end of 
treatment. These points were chosen as screening represents the only period before 
treatment (n=604), cycle 9 represents the end of treatment for patients completing all 9 
treatment cycles (n=283) whereas end of treatment includes respondents at the end of their 
treatment (n=406). Statistical significance of any difference is examined using t-tests. Utilities 
generated using each method were plotted by period to determine whether they show 
comparable movements in quality of life throughout the trial. All statistics were reported using 
all responses where observations were available for every measure of interest. 
 
Correlation and agreement 
The estimates produced using the different methods are compared using Pearson correlation 
coefficients and the intraclass correlation coefficient (ICC). ICC assesses the consistency of 
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the methods given that they are all generating utility values on the same 1-0 full health-dead 
scale. 
 
Differences across classification systems and preference weights 
Further analysis was undertaken to determine why any differences in values were observed 
between EQ-5D and EORTC-8D. This analysis can also be used to highlight whether the 
measures have content validity for this patient group. If EQ-5D and EORTC-8D produce 
different values possible explanations include: classification system; preference weights for 
the classification system; recall period. The recall period is likely to explain some difference 
as EORTC-8D measures health during the past week whereas EQ-5D measures health 
today. This is an issue for research using qualitative analysis and is beyond the scope of this 
paper. Further analysis was here undertaken to explore differences due to the classification 
system and preference weights.  
 
Differences in classification system were examined using Spearman rank correlations of each 
dimension of each measure. Observed frequencies of each dimension are also reported when 
each measure is at full health to determine differences across the measures in ability to 
detect a health improvement at the ceiling of the measure. 
 
Differences in preference weights were analysed using different weightings for EQ-5D. Two 
alternative sets of EQ-5D utility weights were used here (24;25). The first alternative set of 
preference weights by Craig and Busschbach (25) were derived by remodelling the time-
trade-off (TTO) values collected in the MVH study that were used to produce the standard UK 
value set (here referred to as the MVH value set) (10). The model was developed to deal with 
a criticism of how worse than dead responses were modelled to produce the UK MVH value 
set (25). The second alternative set of preference weights by Yang el al. were estimated on 
TTO data collected in a separate study using a small UK general population sample (n=81) 
(24). 
 
Results 
Discrimination 
Severity groups were generated using the Karnofsky performance scale and overall quality of 
life (using a QLQ-C30 item). EORTC-8D had generally higher effect sizes than EORTC QLQ-
C30 and similar effect sizes to EQ-5D (see Table 1). Mapped estimates using both methods 
had higher effect sizes than EQ-5D and the highest effect sizes when severity groups were 
divided by overall quality of life, most likely due to the inclusion of QLQ-C30 global health 
status in both mapping algorithms. The difference in scores across adjacent severity groups 
was statistically significant at the 1% level for all measures. The EORTC-8D had a narrower 
range of mean values across severity groups than EQ-5D (0.597 to 0.852 compared to 0.259 
to 0.810 for severity groups defined using the Karnofsky performance scale). Despite these 
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differences, the smaller standard deviation of EORTC-8D resulted in similar effect sizes to 
EQ-5D. Figure 1 parts a) and c) indicate that EORTC-8D values have a much shallower 
gradient than the other methods, showing smaller differences across different severity groups. 
 
Responsiveness 
The range of utility values covers the full severity range for EQ-5D and EORTC-8D, yet the 
mapped EQ-5D estimates do not reflect the full range of severity at the lower end (Table 2). 
EQ-5D and mapped EQ-5D estimates have a much larger utility range than EORTC-8D due 
to the differences in the utility ranges of the measures. EQ-5D and the Kontodimopoulos et al 
mapped estimates suffer from ceiling effects (12.2% and 11.4% respectively). EORTC QLQ-
C30 summary scores also suffer from ceiling effects (up to 80.3% for one symptom summary 
score), yet the EORTC-8D does not. 
 
The mapped estimates have values above 1 as the mapping algorithms used here were 
estimated using OLS, meaning that predictions are not constrained to 1. As EQ-5D values 
greater than 1 are impossible to obtain this raises the issue of whether we should censor 
mapped EQ-5D estimates above 1. Censoring the values above 1 changes the mean and 
standard deviation of the mapped estimates, and although the change is minimal for the 
McKenzie and van der Pol estimates this would produce a large change for the 
Kontodimopoulos et al estimates from 0.703 (0.250) to 0.695 (0.239). As the mapping 
literature provides no guidance on this, the uncensored mapped estimates are used in all 
analyses. The McKenzie and van der Pol and Kontodimopoulos algorithms correctly predicted 
(1 or above) 19.5% and 51.8% respectively of observed EQ-5D values at 1. 
 
All methods used to produce utility values show significant differences in utilities between 
screening and cycle 9 and between screening and end of treatment (Table 2). The size of the 
change in utilities varies across method with EQ-5D showing the largest mean change with 
the largest standard deviation (0.189 (0.337) between screening and cycle 9) and the 
EORTC-8D showing the smallest mean change and smallest standard deviation (0.049 
(0.143) between screening and cycle 9). For the methods used to produce utilities the effect 
size and standardised response means are largest for the Kontodimopoulos et al estimates 
and smallest for EORTC-8D. Effect sizes and standardised response means for EORTC-8D 
are towards the upper range produced for the EORTC QLQ-C30 summary scores, which may 
be expected given that EORTC-8D is made up of 10 EORTC QLQ-C30 items. Overall the 
EORTC QLQ-C30 global QOL summary score has the highest effect size and standardised 
response mean. Figure 1e) indicates that there is a noticeable gap between the utilities for 
EQ-5D and EORTC-8D, where EORTC-8D values are always higher. The McKenzie and van 
der Pol mapped EQ-5D estimates follow a similar pattern to the EQ-5D, whereas the 
Kontodimopoulos estimates follow a similar pattern to EORTC-8D. 
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The mapped EQ-5D estimates have a lower standard deviation than observed EQ-5D 
estimates and this has been observed elsewhere in the mapping literature. Mapped values 
contain error, measured as the difference between predicted and observed values. Mean 
absolute error is 0.144 for the McKenzie and van der Pol estimates and 0.156 for the 
Kontodimpopoulos et al estimates. Error in predictions increases for more severe health 
states (analysis not reported, available on request), where MAE is more than doubled when 
observed EQ-5D is less than 0.5 compared to EQ-5D greater than or equal to.0.5, and a 
similar pattern has been previously observed in the mapping literature (26). 
 
Correlation and agreement 
Utility values generated using each of the values have high correlation coefficients (Table 3) 
yet the mapped estimates are more highly correlated with EORTC-8D than EQ-5D. This is 
perhaps unsurprising given that the mapped estimates and EORTC-8D are all generated 
using QLQ-C30 responses, but has not been explored in the mapping literature previously. 
 
Differences across classification system and preference weights 
The above analysis demonstrates differences in EQ-5D and EORTC-8D utilities. EQ-5D and 
EORTC-8D dimensions are most highly correlated where expected, such as EQ-5D 
pain/discomfort and EORTC-8D pain (Table 4). The correlations are below 0.5 between all 
EQ-5D dimensions and EORTC-8D fatigue, nausea and constipation/diarrhoea dimensions 
and between EQ-5D self-care and all EORTC-8D dimensions. This suggests differences in 
the quality of life captured by the two classification systems for these dimensions. 
 
Table 5 summarises EORTC-8D responses when EQ-5D=1 meaning that the respondent is in 
full health, demonstrating that the EORTC-8D captures an impact on quality of life according 
to dimensions such as fatigue and physical functioning that are not captured in the EQ-5D for 
these patients. This is most noticeable for fatigue where 52.77% of observations at EQ-5D full 
health have fatigue in the EORTC-8D, similarly 45.71% of observations have problems in the 
physical functioning dimension. Table 6 summarises EQ-5D responses when EORTC-8D=1 
meaning that the respondent is in full health, finding that the EQ-5D captures some 
differences in pain/discomfort and anxiety/depression not captured by EORTC-8D, but the 
proportion of these responses is small (14.08% and 9.23% respectively). 
 
The use of alternative EQ-5D preference weights reduces the range and standard deviation of 
EQ-5D utility values and standard deviation and using the Craig and Bussbach weights raises 
the mean value (Table 7). Mean change is smaller using these alternative preference weights 
(0.059 to 0.098, Table 7) than using the standard UK EQ-5D weights (MVH value set (0.100 
to 0.189, Table 2). Figure 1 parts b), d) and f) demonstrate the pattern of discrimination 
across different severity groups and utility values by period using different preference weights 
for EQ-5D. These figures indicate that the Craig and Busschbach estimates are much closer 
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to EORTC-8D estimates than the standard UK EQ-5D MVH value set. Despite a striking 
resemblance in these graphs summarising data at the mean level, this masks differences at 
the individual level. For example, the correlation between EORTC-8D and Craig and 
Busschbach EQ-5D values is 0.658 (other plots available from authors on request). The Yang 
et al EQ-5D estimates have virtually the same gradient in all of the figures as EORTC-8D, but 
with a systematic difference in mean utilities of around 0.13.  
 
Discussion 
Generic EQ-5D, condition-specific EORTC-8D and two published mapping algorithms were 
used to generate utility estimates for Multiple Myeloma patients in a clinical trial dataset. We 
observed differences in mean utilities and in mean change across time periods using the 
different methods, with the EQ-5D consistently showing the largest mean utility gain. However 
all methods were able to discriminate between severity groups measured using the Karnofsky 
Performance Scale and an overall quality of life item and were responsive. We further 
compared the performance of EORTC-8D to the EORTC QLQ-C30 measure it was derived 
from, finding that discriminative validity and responsiveness of EORTC-8D was comparable to 
the QLQ-C30 functioning and symptom summary scores, but inferior to the QLQ-C30 global 
quality of life summary score. The QLQ-C30 global quality of life score was excluded from the 
health state classification system of EORTC-8D as it is inappropriate for inclusion in a multi-
attribute preference-based measure, yet was included in both the McKenzie and van der Pol 
and Kontodimopoulos et al mapping algorithms and their discriminative validity and 
responsiveness may in part be attributed to this. Analyses have been conducted using one 
patient dataset containing patients with one type of cancer and this is a limitation of this 
research. Replicating these analyses using data for other cancer types is recommended. 
 
The analysis has been performed using observations with no missing data for any of the 
approaches used to generate utilities or EORTC QLQ-C30 summary scores. However, high 
levels of missing data mean that the utilities are not representative of the entire trial sample, 
and this is important as the data may be missing for systematic reasons where patients in the 
poorest health are unable to complete the appropriate questionnaire. Missing values for the 
overall dataset do vary by method, where overall the Kontodimopoulos et al estimates has the 
smallest proportion of missing values (2.2%), followed by EQ-5D (2.8%), with the EORTC-8D 
(4.4%) and the McKenzie and van der Pol estimates (5.1%) having the largest proportions. 
 
Mapping is advantageous as it enables EQ-5D utilities to be estimated when EQ-5D was not 
included in the trial. However these mapped values contain error and should be considered 
only as a second best alternative to including EQ-5D directly in the trial. Here the McKenzie 
and van der Pol algorithm (11) produced more accurate EQ-5D estimates than the 
Kondimopoulos et al algorithm (16) yet both have high mean absolute error. We suggest that 
EORTC-8D utilities are more accurate than these mapped estimates as they do not contain 
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error. However NICE suggests that the mapped estimates should be presented in the main 
economic evaluation analyses and EORTC-8D utilities should be included in a separate 
analysis (6). NICE further recommend that when using condition-specific measures such as 
EORTC-8D researchers should indicate the extent to which their choice of instrument has 
impacted on the valuations. Our findings suggest that the use of EORTC-8D would generate 
lower mean change in utilities with smaller standard deviation than the use of EQ-5D to 
generate utilities for the same cancer patient group. 
 
NICE recommend using the same valuation methodology as the UK valuation of EQ-5D to 
ensure comparability to EQ-5D when using condition-specific measures to produce utilities for 
use in economic evaluation (6). Yet differences between EQ-5D and EORTC-8D were 
observed despite the EORTC-8D using the same valuation methodology as the UK MVH 
valuation of the EQ-5D (10). Further analysis suggested that some of the differences were 
due to the classification system yet some of the differences were due to the preference 
weights. The alternative EQ-5D preference weights produced closer utility estimates to the 
EORTC-8D utilities than the use of the standard UK EQ-5D weights (MVH value set). 
 
Here we have not analysed the impact these differences have on QALY estimates. It is 
possible that the differences in utility values will have an impact on QALY estimates and 
change in QALY estimates, particularly where survival differs across interventions. Two 
studies have compared mapped estimates to direct EQ-5D estimates for use to generate 
QALYs in economic evaluation (11;12). Although both studies found no significant difference 
between QALY estimates generated using mapping to EQ-5D and directly observed EQ-5D 
values, one of these studies found that incremental cost per QALY estimates differed across 
four interventions depending on whether mapped or directly observed EQ-5D values were 
used (12). Research analysing the impact on QALY estimates from using generic or 
condition-specific preference-based measures is recommended. 
 
EQ-5D is not always included in cancer trials, sometimes because it is thought to be 
inappropriate or unresponsive. In contrast, condition-specific measures are often included, as 
they are thought appropriate and responsive. Here EQ-5D has higher responsiveness than 
the condition-specific EORTC-8D and was also able to discriminate between severity groups 
using the Karnofsky Performance Scale and an overall quality of life item from the QLQ-C30. 
This raises the issue of why it is thought the EQ-5D is inappropriate for capturing change in 
cancer patients. Our findings suggest it may be due to content validity, as here 12.2% of EQ-
5D responses are at full health whereas for a large proportion of these observations the 
EORTC-8D captures problems on dimensions such as fatigue and physical functioning. This 
indicates problems with content validity, yet this can only be appropriately determined using 
qualitative analysis which is beyond the scope of this paper. This raises the issue of how to 
determine whether EQ-5D is inappropriate. Guidance suggests that it is not simply a question 
12 
 
of ability to detect a change; content validity has an important role in the new US FDA 
guidance on patient reported outcomes for use in labelling claims (8), and a recent report on 
economic evaluations in cancer found that EQ-5D did not contain all domains thought 
important for sensitivity in an outcome measure for cancer patients (7). 
 
The recommendation of one generic measure such as the EQ-5D for use in all economic 
evaluations is advantageous for comparability, but raises issues of best practice when this 
measure is unavailable or inappropriate. Recommended alternatives are to use mapped 
estimates or other preference-based measures. Our analysis suggests that these methods 
are able to discriminate across severity groups and are responsive, but that the mean change 
and standard deviation across time periods or severity groups is affected by the alternative 
method used, and all methods produced lower mean change and standard deviation than the 
use of EQ-5D directly. Mapped estimates contain error and this will affect the accuracy of the 
utility estimates. In contrast, EORTC-8D estimates captured problems in quality of life at the 
upper end of the utility scale that were not captured by EQ-5D, but overall produced higher 
utility estimates and smaller mean change. The preference-based EORTC-8D performed 
comparably to the non-preference-based EORTC QLQ-C30 measure it was derived from. 
 
 
13 
 
Table 1: Discrimination across severity groups 
Measure Range of mean (s.d.) across groups Range of ES ANOVA 
Karnofsky performance scale (6 severity groups, N=36 to 1410 per group) 
   EQ-5D 0.259 (0.358) to 0.810 (0.179) 0.179 to 0.547 <0.001 
   EORTC-8D 0.597 (0.117) to 0.852 (0.122) 0.354 to 0.497 <0.001 
   McKenzie and van der Pol mapped EQ-5D estimates 0.324 (0.225) to 0.791 (0.192) 0.293 to 0.508 <0.001 
   Kontodimopoulos et al mapped EQ-5D estimate 0.381 (0.206) to 0.879 (0.195) 0.287 to 0.570 <0.001 
   EORTC QLQ-C30 functioning summary scores 16.0 (24.3) to 88.5 (15.5) 0.021 to 0.657 <0.001 
   EORTC QLQ-C30 symptom summary scores 70.2 (25.0) to 4.4 (12.4) -0.012 to -0.476 <0.001 to 0.004 
   EORTC QLQ-C30 global QOL summary score 41.3 (16.0) to 69.05 (17.78) 0.045 to 0.499 <0.001 
    
Overall quality of life (EORTC QLQ-C30 item: 7 severity groups, N=122 to 1688 per group) 
   EQ-5D -0.025 (0.309) to 0.885 (0.184) 0.388 to 0.816 <0.001 
   EORTC-8D 0.483 (0.123) to 0.918 (0.086) 0.550 to 0.811 <0.001 
   McKenzie and van der Pol mapped EQ-5D estimates 0.061 (0.191) to 0.930 (0.135) 0.659 to 1.041 <0.001 
   Kontodimopoulos et al mapped EQ-5D estimate 0.079 (0.162) to 1.080 (0.126) 0.946 to 1.461 <0.001 
   EORTC QLQ-C30 functioning summary scores 12.3 (23.2) to 95.0 (12.2) 0.045 to 0.859 <0.001 
   EORTC QLQ-C30 symptom summary scores 84.3 (20.9) to 1.7 (7.0)  -0.013 to 0.671 <0.001 
Note: ES=effect size, ANOVA=analysis of variance. 
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Table 2: Responsiveness 
 All (n=5650) Screening to cycle 9 (n=255) Screening to end of treatment (n=370) 
  Min Max % at 
worst 
state 
% at (or 
above) 
full 
health 
Mean 
change (s.d.)  
SRM ES Paired 
t-test (P 
value) 
Mean 
change 
(s.d.)  
SRM ES Paired t-
test (P 
value) 
EQ-5D -0.594 1.000 0.02% 12.2% 0.189 (0.337) 0.559 0.539 <0.001 0.100 
(0.371) 
0.270 0.289 <0.001 
EORTC-8D 0.291 1.000 0.01% 3.7% 0.049 (0.145) 0.338 0.329 <0.001 0.021 
(0.154) 
0.137 0.142 0.009 
McKenzie and van der 
Pol mapped EQ-5D 
estimates 
-0.268 1.058 0% 2.5% 0.137 (0.276) 0.495 0.486 <0.001 0.078 
(0.289) 
0.271 0.283 <0.001 
Kontodimopoulos et al 
mapped EQ-5D 
estimate 
-0.181 1.186 0% 11.4% 0.154 (0.263) 0.586 0.581 <0.001 0.084 
(0.302) 
0.278 0.310 <0.001 
EORTC QLQ-C30 
functioning summary 
scores 
0 100 0.5% 
to 
8.4% 
7.4% to 
35.0% 
0.523 
(20.909) to 
11.035 
(24.871) 
0.025 
to 
0.444 
0.023 
to 
0.431 
<0.001 
to 
0.690 
1.216 
(22.341) to 
5.563 
(26.418) 
0.041 
to 
0.211 
0.042 
to 
0.228 
<0.001 to 
0.100 
EORTC QLQ-C30 
symptom summary 
scores 
100 0 0.7% 
to 
5.4% 
8.1% to 
80.3% 
1.569 
(22.665) to -
18.039 
(33.321) 
0.069 
to -
0.541 
0.105 
to -
0.540 
<0.001 
to 
0.270 
-1.441 
(19.269) to 
14.054 
(34.301) 
-0.075 
to -
0.410 
-0.088 
to -
0.422 
<0.001 to 
0.426 
EORTC QLQ-C30 
global QOL summary 
score 
0 100 1.6% 2.6% 14.705 
(25.108) 
0.586 0.664 <0.001 9.437 
(26.532) 
0.356 0.413 <0.001 
Note: SRM=standardised response mean, ES=effect size. 
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Table 3: Correlation and agreement 
Measures Pearson correlation 
coefficient 
ICC (mean (95% confidence 
interval)) 
ICC p 
value 
EQ-5D and EORTC-8D 0.713 0.481 (0.263 to 0.624) <0.001 
EQ-5D and McKenzie and van der Pol mapped EQ-5D estimates 0.757 0.749 (0.737 to 0.760) <0.001 
EQ-5D and Kontodimopoulos et al mapped EQ-5D estimate 0.749 0.713 (0.626 to 0.775) <0.001 
EORTC-8D and McKenzie and van der Pol mapped EQ-5D estimates 0.933 0.638 (0.072 to 0.832) <0.001 
EORTC-8D and Kontodimopoulos et al mapped EQ-5D estimate 0.875 0.721 (0.646 to 0.775) <0.001 
McKenzie and van der Pol mapped EQ-5D estimates and Kontodimopoulos et al 
mapped EQ-5D estimate 
0.921 0.868 (0.517 to 0.943) <0.001 
Note: ICC=Intraclass correlation coefficient. 
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Table 4: Correlation by dimension (n=5650) 
Spearman rank 
correlation 
EQ-5D 
dimensions 
    
EORTC-8D 
dimensions 
Mobility Self-
care 
Usual 
activities 
Pain/ 
discomfort 
Anxiety/ 
depression 
Physical functioning 0.599 0.444 0.610 0.428 0.287 
Role functioning 0.536 0.482 0.654 0.431 0.314 
Pain 0.502 0.437 0.560 0.613 0.332 
Emotional functioning 0.260 0.267 0.343 0.303 0.626 
Social functioning 0.452 0.422 0.588 0.386 0.334 
Fatigue 0.424 0.323 0.496 0.383 0.342 
Nausea 0.204 0.194 0.244 0.207 0.216 
Constipation and 
diarrhoea 
0.219 0.233 0.268 0.255 0.228 
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Table 5: EORTC-8D responses when EQ-5D=1 (n=722) 
EORTC-8D dimensions Level 1 
% 
Level 2 
% 
Level 3 
% 
Level 4 
% 
Level 5 
% 
Physical functioning 54.29 37.12 7.76 0.83 0 
Role functioning 77.01 20.91 1.94 0.14 N/A 
Pain 88.09 11.50 0.42 0 N/A 
Emotional functioning 85.04 14.27 0.28 0.42 N/A 
Social functioning 82.83 15.65 1.39 0.14 N/A 
Fatigue 47.23 48.06 4.57 0.14 N/A 
Nausea 92.94 6.51 0.14 0.42 N/A 
Constipation and diarrhoea 69.39 25.48 3.74 1.39  N/A 
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Table 6: EQ-5D responses when EORTC-8D=1 (n=206) 
EQ-5D dimensions Level 1 
% 
Level 2 
% 
Level 3 
% 
Mobility 96.60 3.40 0 
Self-care 99.03 0.97 0 
Usual activities 99.51 0.49 0 
Pain/discomfort 85.92 14.08 0 
Anxiety/depression 90.78 8.74 0.49 
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Table 7: EQ-5D descriptive statistics using alternative preference weights (n=5650) 
 Craig and Busschbach Yang et al 
Mean (s.d.) 0.741 (0.192) 0.623 (0.185) 
Min -0.298 -0.236 
Max 1 1 
   
Screening to cycle 9 (n=255)   
     Mean change (s.d.)  0.112 (0.232) 0.098 (0.212) 
     SRM 0.496 0.489 
     Effect size 0.509 0.550 
     Paired t-test (P value) p<0.001 p<0.001 
   
Screening to end of treatment (n=370)   
     Mean change (s.d.)  0.061 (0.268) 0.059 (0.237) 
     SRM 0.229 0.243 
     Effect size 0.264 0.299 
     Paired t-test (P value) p<0.001 p<0.001 
Note: SRM=standardised response mean, ES=effect size, ANOVA=analysis of variance 
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Figure 1: Discrimination across severity groups and mean utility values by period 
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a) Discrimination across severity groups 
by Karnofsky Performance Scale 
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c) Discrimination across severity groups 
by overall quality of life 
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e) Utility values by period 
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b) Discrimination across severity groups 
by Karnofsky Performance Scale using 
alternative EQ-5D weights 
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d) Discrimination across severity groups 
by overall quality of life using alternative 
EQ-5D weights 
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f) Utility values by period using alternative 
EQ-5D weights 
 
Note: n<40 for Karnofsky Performance Scale<60 so is not reported for 1a) and 1d). 
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